Cubist looks to dominate antibiotics game
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals could have multiple new drugs on the market within the next few years, making the hospital and acute care-focused company a dominant player in the antibiotics game based on its pipeline assets, acquisitions of Trius Therapeutics and Optimer Pharmaceuticals, and Cubist's advocacy for incentives to encourage antibiotic development.
You may also be interested in...
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Need a specific report? 1000+ reports available
Buy Reports